北京赛特明强医药科技有限公司

Beijing Saite Mingqiang Pharmaceutical Technology (Scitech Pharma) is an innovative biopharmaceutical company founded in 2015 and headquartered in Beijing, China. The company leverages its proprietary AI-driven ultra-large-scale drug design and screening platform, SigmaHit®, to discover and develop small molecule therapeutics targeting oncology, autoimmune diseases, and central nervous system disorders. Its lead candidate, ST-1898, is an AI-designed multi-target tyrosine kinase inhibitor currently in Phase II/III clinical trials for radioactive iodine-refractory differentiated thyroid cancer, as well as Phase II trials for melanoma and renal cell carcinoma. Other clinical assets include ST-1703, a HER2 inhibitor for advanced solid tumors, and ST-1839 for non-small cell lung cancer.